FH Blocking Peptide

Cat# MBS9626808-1mg

Size : 1mg

Brand : MyBiosource

Contact local distributor :


Phone : +1 850 650 7790

Fh Blocking Peptide – The purity is >90%,tested by HPLC and MS. Purity

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS9626808

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the… More details

Product Overview

Online Datasheet in PDF
Product Name
FH, Blocking Peptide
Full Product Name
FH Blocking Peptide
Product Gene Name
FH blocking peptide
Product Synonym Names
FH; Fumarase; Fumarate hydratase; Fumarate hydratase mitochondrial; Fumarate hydratase, mitochondrial; FUMH_HUMAN; HLRCC; LRCC; MCL; MCUL 1; MCUL1; MS709; Multiple hereditary cutaneous leiomyomata
Form/Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.
Purity/Purification
The purity is >90%,tested by HPLC and MS.
Preparation and Storage
Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.
Antibody/Peptide Pairs
FH peptide (MBS9626808) is used for blocking the activity of FH antibody (MBS9608096)
Molecular Weight
54,637 Da
Chromosome Location
Chromosome: 1; NC_000001.10 (241660857..241683085, complement). Location: 1q42.1
OMIM
136850
Supply Chain Verification
Manufactured in a lab with traceable raw materials manufactured on site. Coordinated product portfolio of antibodies, pairs, conjugates, recombinant proteins, and immunoassay materials available, please inquire.
Notes
For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.
Applications Tested/Suitable for FH blocking peptide
Blocking/Control

Other Notes

Small volumes of FH blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for FH purchase

MBS9626808 is a blocking peptide targeting FH.

Additional Details

NCBI/Uniprot data below describe general gene information for FH. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
fumarate hydratase, mitochondrial
NCBI Official Synonym Full Names
fumarate hydratase
NCBI Official Symbol
FH
NCBI Official Synonym Symbols
MCL; LRCC; HLRCC; MCUL1
UniProt Protein Name
Fumarate hydratase, mitochondrial
Protein Family
FH protein interacting protein
UniProt Gene Name
FH
UniProt Synonym Gene Names
Fumarase
UniProt Entry Name
FUMH_HUMAN
NCBI Protein Information
fumarate hydratase, mitochondrial; fumarase

NCBI Summary for FH

The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy. [provided by RefSeq, Jul 2008]
Show more

UniProt Comments for FH

FH: a metabolic enzyme that participates in the tricarboxylic acid cycle that catalyzes the conversion of (S)-malate into fumarate + H2O. There are two substrate binding sites: the catalytic A site, and the non-catalytic B site that may play a role in the transfer of substrate or product between the active site and the solvent. Alternatively, the B site may bind allosteric effectors. Fumarate accumulates in the cell when FH is inactivated. Fumarate inhibits the dioxygenases that hydroxylate the transcription factor HIF and leads to its degradation by VHL. Since HIF turns on oncogenic pathways, FH has apparent tumor suppressor activity. Defects in FH are the cause of hereditary leiomyomatosis and renal cell cancer (HLRCC), a highly metastatic form of RCC. Defects in FH are the cause of fumarase deficiency (FD) also known as fumaricaciduria. FD is characterized by progressive encephalopathy, developmental delay, hypotonia, cerebral atrophy and lactic and pyruvic acidemia. Cells derived from a patient with HLRCC exhibit compromised oxidative phosphorylation, dependence on anaerobic glycolysis, rapid glycolytic flux, and overexpression of lactate dehydrogenase A (LDHA) and GLUT1. Two human isoforms are produced by alternative initiation. The longer isoform is mitochondrial, while the shorter form, missing residues 1-43, is cytoplasmic.

Protein type: Lyase; Tumor suppressor; Carbohydrate Metabolism - citrate (TCA) cycle; EC 4.2.1.2; Mitochondrial

Chromosomal Location of Human Ortholog: 1q42.1

Cellular Component: tricarboxylic acid cycle enzyme complex; mitochondrion; mitochondrial matrix; cytoplasm

Molecular Function: fumarate hydratase activity

Biological Process: cellular metabolic process; fumarate metabolic process; tricarboxylic acid cycle; homeostasis of number of cells within a tissue

Disease: Fumarase Deficiency
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Products associated with FH blocking peptide

 Reference Product  PubMed Publications
 SDHB blocking peptide  >11 publications with FH and SDHB
 SDHD blocking peptide  >5 publications with FH and SDHD
 SDHC blocking peptide  >4 publications with FH and SDHC
 SOD2 blocking peptide  >3 publications with FH and SOD2
 SDHA blocking peptide  >2 publications with FH and SDHA
 MDH1 blocking peptide  >2 publications with FH and MDH1
 MDH2 blocking peptide  >1 publications with FH and MDH2

Pathways associated with FH blocking peptide

 Products by Pathway  Pathway Diagram
 Carbon Metabolism Pathway antibodies  Carbon Metabolism Pathway Diagram
 Carbon Metabolism Pathway antibodies  Carbon Metabolism Pathway Diagram
 Citrate Cycle (TCA Cycle) Pathway antibodies  Citrate Cycle (TCA Cycle) Pathway Diagram
 Citrate Cycle (TCA Cycle) Pathway antibodies  Citrate Cycle (TCA Cycle) Pathway Diagram
 Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway antibodies  Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway Diagram
 Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway antibodies  Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway Diagram
 Citric Acid Cycle (TCA Cycle) Pathway antibodies  Citric Acid Cycle (TCA Cycle) Pathway Diagram
 Conversion Of Glucose To Acetyl CoA And Entry Into The TCA Cycle Pathway antibodies  Conversion Of Glucose To Acetyl CoA And Entry Into The TCA Cycle Pathway Diagram
 Metabolism Pathway antibodies  Metabolism Pathway Diagram
 Pathways In Cancer antibodies  Pathways In Cancer Diagram

Diseases associated with FH blocking peptide

 Disease Name  Pubmed Publications
 Neoplasms Antibodies  >498 publications with FH and Neoplasms
 Nervous System Diseases Antibodies  >325 publications with FH and Nervous System Diseases
 Kidney Diseases Antibodies  >251 publications with FH and Kidney Diseases
 Brain Diseases Antibodies  >203 publications with FH and Brain Diseases
 Inflammation Antibodies  >113 publications with FH and Inflammation
 Adenocarcinoma Antibodies  >90 publications with FH and Adenocarcinoma
 Hyperplasia Antibodies  >81 publications with FH and Hyperplasia
 Anemia Antibodies  >70 publications with FH and Anemia
 Necrosis Antibodies  >68 publications with FH and Necrosis
 Skin Neoplasms Antibodies  >64 publications with FH and Skin Neoplasms

Organs/Tissues associated with FH blocking peptide

 Organ/Tissue Name  Pubmed Publications
 Blood Antibodies  >2028 publications with FH and Blood
 Heart Antibodies  >707 publications with FH and Heart
 Vascular Antibodies  >435 publications with FH and Vascular
 Liver Antibodies  >306 publications with FH and Liver
 Bone Antibodies  >283 publications with FH and Bone
 Kidney Antibodies  >256 publications with FH and Kidney
 Brain Antibodies  >239 publications with FH and Brain
 Skin Antibodies  >190 publications with FH and Skin
 Muscle Antibodies  >170 publications with FH and Muscle
 Lung Antibodies  >114 publications with FH and Lung